Team2020-02-24T02:34:43-05:00
Page-TitleTEAM

Virpax Pharmaceuticals specializes in developing new drug delivery systems across various indications in order to increase compliance and maximize the ability to achieve full therapeutic efficacy.

What we do is important, but how we do it is just as important. As we drive our business forward, we must not lose sight of our fundamental commitment to doing business the right way. I expect people at all levels to always do the right thing, not just the easy thing – and to be motivated, empowered and supported in doing so.

Only by living up to our core values, wherever Virpax Pharmaceuticals Inc. has a presence or an impact, can we maintain the trust of our stakeholders and broader society that is so vital to our reputation and license to do business.

The Virpax Pharmaceuticals Inc. Code of Ethics & Business Conduct (the ”Code”) is our guide to understanding how our high level values are to be translated into consistent actions worldwide. It provides guidance about what is expected of each of us as we work to achieve our business goals. I expect you to study it closely and to live by its principles in your day-to-day business activities.

We are all responsible for making sure that nothing, including the need to meet objectives, direct orders from a more senior employee, or pressure from colleagues, ever compromises our commitment to honesty and integrity.

Compliance with this Code is mandatory for all Virpax Pharmaceuticals Inc. employees and consultants worldwide. It provides the framework for the application of consistent standards of responsible behavior that will ensure that Virpax Pharmaceuticals Inc. is an organization that is valued and respected by society and for which we are all proud to work.

ANTHONY P. MACK
CEO of Virpax Pharmaceuticals

OUR CODE OF ETHICS & BUSINESS CONDUCT

READ MORE
SubheadEXECUTIVE LEADERSHIP
ANTHONY P. MACK, MBA2020-02-23T14:42:10-05:00

Chairman + CEO

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX’s lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2020-02-23T14:42:14-05:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New Jersey Medical School.  Dr. Gudin is Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. He is an active speaker in the field of pain management. His clinical and research focus includes pain management, opioid abuse and potential solutions, and increasing clinician awareness of pain assessment and risk management. Dr. Gudin completed a residency in anesthesiology at Yale University School of Medicine, in New Haven, Connecticut. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

MICHÈLE C. LINDE, JD2020-02-23T14:42:19-05:00

EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary

Michèle C. Linde has more than 25 years of in-house and private legal practice experience with a focus on global life sciences. She has worked extensively with branded and generic pharmaceuticals, medical devices, academic, and corporate clients in the global market. With a broad- based practice, Ms. Linde has negotiated complex global transactions; implemented corporate compliance programs and has extensive experience in government affairs, corporate governance, anti-corruption and critical areas of pharmaceuticals and medical device law practices. Ms. Linde served as the General Counsel of Akloma Bioscience AB and she served at the law firm Mannheimer Swartling in Stockholm. Ms. Linde has also served as a Vice President of Endo Pharmaceuticals in the United States and she has also worked in the law departments of AstraZeneca, Bristol Myers Squibb (in Belgium), and DuPont Pharmaceuticals.

GERALD W. BRUCE2020-02-23T14:42:24-05:00

Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative and held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 Billion in sales. He later served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for the Bristol-Myers Squibb $7 billion US portfolio. Mr. Bruce went on to become the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company’s first product for the treatment of Heart Failure. He also spent close to ten years in the Medical Nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division. Mr. Bruce currently serves on the Board of Trustees for Lincoln University and is a Board member for the National Sales Network. He received his bachelor’s degree in Business Administration from Lincoln University and a master’s degree in Leadership from the McDonough School of Business at Georgetown University.

MICHAEL M. AIELLO, CPA2020-02-23T14:42:32-05:00

Michael M. Aiello has more than 16 years of public and private accounting experience. Since June 2011, he has been the Managing Partner of Centri Business Consulting, LLC, a rapidly growing consulting firm that assists public companies in the life sciences and technology sector with the preparation of periodic reports required to be filed with the Securities and Exchange Commission and compliance with Section 404 of the Sarbanes Oxley Act of 2002 . Prior to his time with Centri, he was Capital Gold Corporation’s Corporate Controller from 2007 until their sale to Gammon Gold in a $420 million deal in 2011. He was an Assurance Manager with BDO USA, LLP where he managed several large public and private engagements across various industries including Life Sciences, Technology, Manufacturing and Real Estate. Mr. Aiello was an Audit and Accounting Senior at Maillie, Falconiero & Company. He received a B.S. in Accounting from the Pennsylvania State University and is a Certified Public Accountant.

OVER 100+ YEARS

OF COMBINED EXECUTIVE EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

COLLECTIVELY LED THE WAY TO

OVER 40 NDA
APPROVALS

SubheadBOARD MEMBERS
ANTHONY P. MACK, MBA2020-02-23T14:42:10-05:00

Chairman + CEO

Anthony P. Mack has more than 25 years of experience in the pharmaceutical and finance industries. Prior to founding VIRPAX in 2016, Mr. Mack founded SCILEX Pharmaceuticals and served as President and CEO until ZTlido was approved in February 2018. Mr. Mack founded his first pharmaceutical company ProSolus Pharmaceuticals in 2009, where he served as President before selling the company to Mission Pharmacal in 2015. Mr. Mack has held high-level management positions with Purdue Pharma, Endo Pharmaceuticals, Novartis, and EKR Therapeutics. He has led training, marketing, and commercial distribution for billion-dollar pain management products and has forged key strategic alliances. Mr. Mack has served as Founder, Director, and Executive Officer of both ProSolus Pharmaceuticals Inc. and SCILEX Pharmaceuticals. After SCILEX’s lead product, ZTlido, was approved for commercialization by the FDA, SCILEX was sold to a publicly traded company. Mr. Mack also founded and serves as Director of IACTA Pharmaceuticals Inc. By serving on executive boards, Mr. Mack has utilized his skills and experience to implement policies relating to corporate governance and overall business strategy. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2020-02-23T14:42:14-05:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center in New Jersey for almost 20 years. He is a Clinical Associate Professor in Anesthesiology at the Rutgers New Jersey Medical School.  Dr. Gudin is Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. He is an active speaker in the field of pain management. His clinical and research focus includes pain management, opioid abuse and potential solutions, and increasing clinician awareness of pain assessment and risk management. Dr. Gudin completed a residency in anesthesiology at Yale University School of Medicine, in New Haven, Connecticut. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching.

MICHÈLE C. LINDE, JD2020-02-23T14:42:19-05:00

EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary

Michèle C. Linde has more than 25 years of in-house and private legal practice experience with a focus on global life sciences. She has worked extensively with branded and generic pharmaceuticals, medical devices, academic, and corporate clients in the global market. With a broad- based practice, Ms. Linde has negotiated complex global transactions; implemented corporate compliance programs and has extensive experience in government affairs, corporate governance, anti-corruption and critical areas of pharmaceuticals and medical device law practices. Ms. Linde served as the General Counsel of Akloma Bioscience AB and she served at the law firm Mannheimer Swartling in Stockholm. Ms. Linde has also served as a Vice President of Endo Pharmaceuticals in the United States and she has also worked in the law departments of AstraZeneca, Bristol Myers Squibb (in Belgium), and DuPont Pharmaceuticals.

ERIC FLOYD, PhD2020-02-11T20:08:56-05:00

Dr. Eric Floyd currently serves as Chief Regulatory Officer at Neurogene Inc. He has nearly 21 years of regulatory experience within the pharmaceutical industry. Most recently, he was Senior Vice President, Regulatory Affairs, for Axovant Sciences.  He served as President of Compliance Services and Chief Scientific Officer at Dohmen Life Science Services, Inc., Senior Vice President, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd received a Ph.D. in Neurophysiology from Meharry Medical College, Nashville, an executive MBA from St. Joseph’s University, Philadelphia, an MS from Tennessee State University, a BS from the University of Illinois and has served as an Assistant Professor at Harvard University School of Medicine. Dr. Floyd served as an outside director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016.

JERROLD SENDROW, CFP2020-02-11T20:09:17-05:00

Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains a moderate practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016. In addition, up through 2014, Mr. Sendrow has more than 35 years of experience as Chief Financial Officer and Director in companies with revenues in excess of $500 million. Jerry has led these companies through start-up, survival, turnaround and growth modes. Prior to that, Mr. Sendrow was an accountant in the audit departments of Touche Ross & Co. and Peat Marwick Mitchell & Co after returning from military service of two tours in the Vietnam conflict. Mr. Sendrow holds business degrees from Bernard Baruch College of the City University of New York and Adelphi University.

THANI JAMBULINGAM, PhD2020-02-11T20:09:39-05:00

Dr. Thani Jambulingam is a Pfizer Fellow and Professor in the Department of Pharmaceutical and Healthcare Marketing at St Joseph’s University, Erivan K. Haub School of Business, in Philadelphia, Pennsylvania, USA. He teaches in the executive MBA program for biopharmaceutical, medical device and physician executives. Dr. Jambulingam served as the chair of the department for 8 years. He is trained at Harvard in case method for teaching. Dr. Jambulingam’s research interests are in pharmaceutical and healthcare strategy, and innovation and published in marketing and management journals. Dr. Jambulingam has also served as a consultant and facilitated training sessions in innovation and strategy for senior leadership and/or brand teams within several small, mid and large pharma and healthcare firms including Alkermes, Abbott, Astra Zeneca, Lancaster General, Merck, Novo Nordisk, Pfizer, Solvay and Procter & Gamble. During his sabbatical, he joined Pfizer with the Prevenar Global Commercial Team contributing to development of Prevenar franchise positioning, healthy aging platform development, vaccine business strategy for emerging markets, pediatric expanded age strategy (life cycle management) and conducted strategy session for executive leadership within the specialty care division of Pfizer. Dr. Jambulingam is a pharmacist and obtained his Ph.D. from University of Wisconsin-Madison.

CalloutEXPERIENCED COMMERCIAL MANAGEMENT TEAM WITHPROVEN TRACK RECORDSLAUNCHING AND MARKETING MULTIPLE PAIN PRODUCTS

LEARN HOW YOU CAN JOIN OUR TEAM AND TRANSFORM PAIN RELIEF

LEARN MORE